ClinicalTrials.gov
ClinicalTrials.gov Menu

Triamcinolone Acetonide as an Adjunctive to VPDT in ARMD.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00148551
Recruitment Status : Unknown
Verified July 2007 by Canadian Retinal Trials Group.
Recruitment status was:  Active, not recruiting
First Posted : September 8, 2005
Last Update Posted : July 30, 2007
Sponsor:
Collaborators:
University of British Columbia
QLT Inc.
Vancouver Hospital
Information provided by:
Canadian Retinal Trials Group

Brief Summary:
A 24 - month Study looking at the the changes in visual acuity of patients receiving PDT therapy in conjunction with intravitreal triamcinolone.

Condition or disease Intervention/treatment Phase
Age-Related Macular Degeneration Drug: Triamcinolone Acetonide Phase 2 Phase 3

Detailed Description:
This study will evaluate the effect of Triamcinolone Acetonide in conjunction with photodynamic therapy for the treatment of sub-foveal choroidal neovascular membranes secondary to age-related macular degeneration.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Triamcinolone Acetonide as an Adjunctive Treatment to Verteporfin Therapy in Neovascular Age-Related Macular Degeneration: Randomized Placebo-Controlled Clinical Trial.
Study Start Date : January 2004
Estimated Study Completion Date : March 2008





Primary Outcome Measures :
  1. Changes in visual acuity from baseline.

Secondary Outcome Measures :
  1. Change in lesion characteristics from baseline.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Individuals with predominantly classic, subfoveal CNV secondary to AMD.
  • No previous PDT Treatment in study eye.

Exclusion Criteria:

  • CNV from conditions, other than AMD.
  • Other disease that could be responsible for decreased vision.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00148551


Locations
Canada, British Columbia
Eye Care Centre
Vancouver, British Columbia, Canada
Sponsors and Collaborators
Canadian Retinal Trials Group
University of British Columbia
QLT Inc.
Vancouver Hospital
Investigators
Study Director: David A Maberley, M.D. University of British Columbia

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00148551     History of Changes
Other Study ID Numbers: 01 (C03 - 0236)
First Posted: September 8, 2005    Key Record Dates
Last Update Posted: July 30, 2007
Last Verified: July 2007

Keywords provided by Canadian Retinal Trials Group:
AMD
Triamcinolone
Macular Degeneration

Additional relevant MeSH terms:
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Triamcinolone hexacetonide
Triamcinolone
Triamcinolone Acetonide
Triamcinolone diacetate
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Immunosuppressive Agents
Immunologic Factors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action